

Research Laboratories, Indianapolis, for helpful correspondence and data in advance of publication on the relevant patents.

## References and Notes

- (1) W. S. Marshall, British Patent (to Eli Lilly & Co.) 1 377 480 (1974).
- (2) W. S. Marshall, U.S. Patent (to Eli Lilly & Co.) 3 600 437 (1971).
- (3) Netherlands Patent (to Ciba) 6903 273 (1969).
- (4) Netherlands Patent (to Merck, A.G.) 6 810 359 (1969). We had prepared some of the compounds claimed, including 26–29, before these patents were issued.
- (5) C. A. Winter, E. A. Risley, and G. W. Nuss, *Proc. Soc. Exp. Biol. Med.*, 111, 544 (1962); D. W. Dunwell, D. Evans, T. A. Hicks, C. H. Cashin, and A. Kitchen, *J. Med. Chem.*, 18, 53 (1975).
- (6) W. G. Kenyon, R. B. Meyer, and C. R. Hauser, *J. Org. Chem.*, 28, 3108 (1963).
- (7) M. D. Nair and R. Adams, *J. Am. Chem. Soc.*, 83, 3518 (1961).
- (8) R. A. W. Johnstone, D. W. Payling, and C. Thomas, *J. Chem. Soc. C*, 2223 (1969).
- (9) H. T. Openshaw and N. Whittaker, *J. Chem. Soc. C*, 89 (1969).
- (10) E. C. Horning, A. F. Finelli, W. S. Johnson, and H. Wynberg, "Organic Syntheses", Collect. Vol. IV, Wiley, New York, 1963, p 461.
- (11) R. E. Bowman and W. D. Fordham, *J. Chem. Soc.*, 2578 (1951).

## Potential Antiinflammatory Compounds. 3.<sup>1</sup> Compounds Derived from Acenaphthene and Indan

Christine E. Smith, W. R. Nigel Williamson,\*

*Organic Chemistry Department*

Colin H. Cashin, and E. Ann Kitchen

*Pharmacology Department, Lilly Research Centre Ltd., Windlesham, Surrey GU20 6PH, England. Received October 27, 1978*

Compounds having acenaphthene and indan as their parent nuclei were synthesized for antiinflammatory testing. Compounds which showed activity were 1-phenyl-5-acenaphthenylacetic acid and its  $\alpha$ -methyl derivative (carrageenan rat paw edema) and the same  $\alpha$ -methylacenaphthenylacetic acid and 2-(4-chlorobenzylidene)-3-oxo-5-indanacetic acid and its  $\alpha$ -methyl derivative (rat adjuvant arthritis). None of the compounds was more active than the control compounds phenylbutazone and indomethacin.

In recent years, numerous attempts have been made to obtain compounds which could show superior antiinflammatory activities to those of the first compounds related to acetic and propionic acids to reach the clinic, indomethacin and ibufenac.<sup>2</sup> We chose to investigate two systems (exemplified by compounds 12, Scheme I, and compound 31, Scheme II) based on acenaphthene and indan. A factor in the choice of these nuclei was the activity<sup>3</sup> of the sulfonic acid derivatives of acenaphthene and indan as inhibitors of denaturation of protein by heat.<sup>4</sup>


In the indan series, we also took the opportunity of the availability of 3-oxo-5-indanacetic acid, 17, and later  $\alpha$ -methyl-3-oxo-5-indanacetic acid (37) to prepare three condensation products with aldehydes (see Scheme II, 18, 19, and 38). 1-Methyl-5-phenylindan (23) was prepared, since it is a neutral compound which could possibly be metabolized in vivo to 5-phenylindan-1-carboxylic acid, an analogue of the active 5-cyclohexylindan-1-carboxylic acid.<sup>6</sup>

**Chemistry. Acenaphthene Series.** The route employed to the key compounds (12, R = H and Me) is outlined in Scheme I. The reaction sequence was partially derived from that used by Anderson and Wade<sup>7</sup> in their synthesis of a tetrahydro-5-acenaphtheneacetic acid.

The intermediates 2, 3, 5–7, 10, and 11 were not obtained pure but were characterized, as appropriate, by means of IR and/or NMR spectra. The intermediate 2 was a mixture of double-bond isomers (indicated in the diagram), but the tendency for exocyclic bond formation to occur in the six-membered ring analogues 10 was much less: 10% exocyclic form occurred at most. Further details of the successful routes are given in Table I and the Experimental Section.

**Indan Series.** Initially, we attempted the preparation of 1-phenylindan-5- and -6-acetic acids, but the cyclization of the dicarboxylic acid 15 prepared according to the method of Bruice and Bradbury<sup>8</sup> gave the isomer 16 rather than the required 1-phenyl-3-oxo-5-indanacetic acid (see Scheme II). After other unsuccessful routes had been abandoned, we turned to the synthesis of 1-cyclohexyl-5-indanacetic acid (30). The route is outlined in Scheme II. The intermediates 26–29 were not obtained pure but were characterized by IR and/or NMR spectra. Compound 26 was a mixture of double-bond isomers, but otherwise the synthesis was straightforward. The route used for the preparation of 17 and 37, the intermediates for the condensation products 18, 19, and 38, is also outlined in Scheme II. 4-Biphenylpropenyl ketone 24 was cyclized to 3-methyl-5-phenyl-1-indanone (25). The indanone 25 was isomeric with 3-methyl-6-phenyl-1-indanone (22), which was hydrogenolyzed to give 1-methyl-5-phenylindan (23). Further details are given in Tables II and III and the Experimental Section.

**Antiinflammatory Activity.** The results of antiinflammatory testing against carrageenan-induced foot edema of Winter et al.<sup>10</sup> in rats, modified as indicated in ref 11, are reported in Tables I and III. The results of testing on rat adjuvant arthritis<sup>12</sup> for compounds 12 (R<sup>1</sup> = H and Me), 16, 19, and 38 are also given in footnotes to Tables I and III. Of the three types of acidic compounds examined, i.e., the acenaphthenes 12, the indans 30 and 31, and the benzylidene indanones 18, 19, and 38, only the acenaphthenes were significantly active in the carrageenan-induced foot edema, while one acenaphthene (12, R<sup>1</sup> = Me) and two benzylidene indanones (19 and 38) showed activity

Scheme I. Preparation of Compounds in the Acenaphthene Series<sup>a</sup>

<sup>a</sup> Reagents for method A: Zn, BrCH(R)CO<sub>2</sub>Et (R = H, Me); B (i) (for 3), H<sub>2</sub>, Pd/C, EtOH, 1 h; B (ii), 2 N NaOH reflux 3.5 h, H<sup>+</sup>; C (i), LiAlH<sub>4</sub> on 3; C (ii), 49% HBr on 5; C (iii), NaCN on 6; D, concentrated HCl; E, PCl<sub>5</sub> in C<sub>6</sub>H<sub>6</sub>; F, Pd/C, 200 °C; F (i), 2 N NaOH, reflux 3.5 h, H<sup>+</sup>.

Table I. Intermediates 1, 4, and 8 of the Acenaphthene Series and Acenaphthenes 12

| no. | R <sup>1</sup>                      | R <sup>2</sup>                                    | mp, °C             | method           | yield, % | purifn proced <sup>a</sup> | formula  | anal. | antiinflam <sup>b</sup> act. vs. carrageenan |                     |  |
|-----|-------------------------------------|---|--------------------|------------------|----------|----------------------------|--|-------|--|---------------------|--|
|     |                                     |   |                    |                  |          |                            |  |       | dose, mg/kg po $\times$ 2                    | % redn              | ca. LD <sub>50</sub> in mice, mg/kg po |
| 1   | R <sup>1</sup> + R <sup>2</sup> = O |   | 71-72 <sup>j</sup> | j                | 61       | I                          | C <sub>15</sub> H <sub>12</sub> O              | C, H  | 100  | *48 <sup>c, h</sup> | 1600                                   |
| 4   | H                                   | CH <sub>2</sub> CO <sub>2</sub> H                 | 126-129            | A-B <sup>1</sup> | 84       | II                         | C <sub>17</sub> H <sub>16</sub> O <sub>2</sub> | C, H  | 100  | 0 <sup>d</sup>      | 1600                                   |
| 8   | H                                   | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H | 124-125            | C-D              | 75       | II                         | C <sub>18</sub> H <sub>18</sub> O <sub>2</sub> | C, H  | 25   | 0 <sup>e</sup>      | 300                                    |
| 12  | H                                   |   | 200                | B <sup>1</sup>   | 45       | III                        | C <sub>20</sub> H <sub>16</sub> O <sub>2</sub> | C, H  | 100  | *53 <sup>f, h</sup> | 400                                    |
| 12  | Me                                  |   | 199-200            | B <sup>1</sup>   | 18       | IV                         | C <sub>21</sub> H <sub>18</sub> O <sub>2</sub> | C, H  | 100  | *44 <sup>g, h</sup> | 1600                                   |

<sup>a</sup> I, recrystallization from EtOAc-light petroleum (bp 40-60°); II, recrystallization from aqueous MeOH; III, trituration with Et<sub>2</sub>O; IV, recrystallization from EtOH. <sup>b</sup> An asterisk indicates that the result is significant on Student's *t* test at *p* < 0.01. <sup>c</sup> Control compound phenylbutazone gave 70% reduction of edema at 2  $\times$  50 mg/kg (*p* < 0.001). <sup>d</sup> Hydrocortisone control: 73% reduction at 2  $\times$  50 mg/kg (*p* < 0.001). <sup>e</sup> Phenylbutazone control: 40% reduction at 2  $\times$  50 mg/kg (*p* < 0.02). <sup>f</sup> Phenylbutazone control: 69% reduction at 2  $\times$  50 mg/kg (*p* < 0.001). <sup>g</sup> Phenylbutazone control: 51% reduction at 2  $\times$  50 mg/kg (*p* < 0.001) (all doses po). <sup>h</sup> In the rat adjuvant arthritis test<sup>12</sup> compound 1 showed 36% reduction of the swelling in the noninjected foot using 16 daily po doses of 100 mg/kg; control compound phenylbutazone, 90% reduction at 16  $\times$  33 mg/kg; compound 12 (R<sup>1</sup> = H), 0% reduction at 16  $\times$  100 mg/kg; control compound phenylbutazone, 50% reduction at 16  $\times$  50 mg/kg; compound 12 (R<sup>1</sup> = Me), 50% reduction at 16  $\times$  50 mg/kg; control compound phenylbutazone, 90% reduction at 16  $\times$  50 mg/kg; *p* values for the results of experiments using the adjuvant arthritis test were not calculated since only three rats could be used per drug; however, daily measurements of parameters were made and comparisons of the effects of drugs in dosed animals relative to undosed control rats were evaluated by a graphical method. <sup>j</sup> Reference 9 gives mp 78 °C.


in rat adjuvant arthritis when dosed at 50 and 100 mg/kg. The magnitude of the activities of the compounds relative to those obtained using the control compounds, phenylbutazone and indomethacin, did not encourage further development of the compounds, including resolution of the diastereoisomers, or separation of the *E* and *Z* forms of the benzylidene compounds. The activity of two neutral compounds (1 and 23) indicates that activity in these tests is not a prerogative of acidic compounds; this has been shown before in the case of compounds such as indoxole.<sup>2</sup> The activity of 1 and 23 may, of course, be due to the formation of acidic metabolites.

## Experimental Section

Melting points are uncorrected. Microanalyses were carried out by Mr. G. Maciak and associates, Eli Lilly & Co., Indianapolis,

Ind., and microanalytical results were within  $\pm 0.4\%$  of the theoretical values. IR (Perkin-Elmer 457 spectrophotometer) and NMR (Varian A 60-A spectrometer) spectra were obtained for all of the compounds and were consistent with the given structures. Examples of the methods are given below. Further details of the compounds are given in Tables I-III.

**Method A. 3-Phenyl-1-indanacetic Acid (4).** 3-Phenyl-1-indanone (83 g, 0.4 mol) was dried by refluxing in C<sub>6</sub>H<sub>6</sub> (120 mL) with removal of the azeotroped H<sub>2</sub>O. To this solution was added Et<sub>2</sub>O (120 mL) and Zn wool (26.25 g, 0.4 mol). The reaction mixture was heated to near reflux and a crystal of I<sub>2</sub> added. Ethyl bromoacetate (110 g, 0.6 mol) was added over 2 h, the temperature being kept near reflux by heat of reaction and some external heating. After the addition of ethyl bromoacetate, the mixture was stirred and refluxed for a further 0.5 h, cooled, and poured into ice and AcOH. The mixture was extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O was washed with 1% NH<sub>4</sub>OH, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and

Scheme II. Preparation of Compounds in the Indan Series<sup>a</sup>

<sup>a</sup> Reagents for method G, S and morpholine at 130–140 °C for 6 h, 50% NaOH, EtOH, reflux 6 h, H<sup>+</sup>; method H, polyphosphoric acid at 95–100 °C for 0.5–1 h; method J, ArCHO–4% KOH in EtOH, 0.6–2 h, H<sup>+</sup>; method K, EtOH–concentrated HCl, reflux 18 h; method L, NaOEt–Et<sub>2</sub>CO<sub>3</sub>, 100 °C; method M, NaOEt–MeI, reflux 3 h; method N, KOH–EtOH, room temperature, 96 h, H<sup>+</sup>; method P, 10% concentrated HCl in AcOH, room temperature for 5 days; method R, H<sub>2</sub>–10% Pd/C in EtOH, trace HCl, 60 psi; method S, MeCH=CHCOCl in CH<sub>2</sub>Cl<sub>2</sub>, AlCl<sub>3</sub>, 1.75 h at 25 °C; method T, AlCl<sub>3</sub>–NaCl at 140–180 °C, 2 min; method U, A, followed by P<sub>2</sub>O<sub>5</sub>–C<sub>6</sub>H<sub>6</sub> reflux of product, 3.5 h; method V, AcCl–AlCl<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 50 min; method W, 85% (NH<sub>4</sub>)<sub>2</sub>–85% KOH in (CH<sub>3</sub>)<sub>2</sub>(OH)<sub>2</sub>, reflux 1.5 h, 190–200 °C, 4 h, formation of Na salt. <sup>b</sup> Reference 8.

Table II. Intermediates of Indian Series<sup>a</sup>


| no. | R <sup>1</sup>   | R <sup>2</sup>                                      | mp or bp<br>(mm), °C | meth-<br>od | yield,<br>% | purifn<br>proced <sup>b</sup> | formula  | anal. |
|-----|--|---|----------------------|-------------|-------------|-------------------------------|--|-------|
|     |  |   |                      |             |             |                               |  |       |
| 14  | HO <sub>2</sub> CCH <sub>2</sub>   | -(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H  | 185-187              | G           | 64          | I                             | C <sub>11</sub> H <sub>12</sub> O <sub>4</sub> | C, H  |
| 15  | HO <sub>2</sub> CCH <sub>2</sub>   | -CH(Ph)CH <sub>2</sub> CO <sub>2</sub> H            | 159 <sup>c</sup>     | c           | 30          | c                             | C <sub>17</sub> H <sub>16</sub> O <sub>4</sub> | C, H  |
| 24  | Ph   | -COCH=CHMe  | 80-82                | S           | 47          | III                           | C <sub>16</sub> H <sub>14</sub> O <sub>4</sub> | C, H  |
| 28  | c-C <sub>6</sub> H <sub>11</sub> -CH(CH <sub>2</sub> CO <sub>2</sub> Et) | -Ac   | 178 (0.29)           | V           | 45          | IV                            | C <sub>19</sub> H <sub>20</sub> O <sub>3</sub> | C, H  |
| 32  | EtO <sub>2</sub> CCH <sub>2</sub> -                                      | -(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> Et | 132-134 (0.07)       | K           | 53          | IV                            | C <sub>15</sub> H <sub>20</sub> O <sub>4</sub> | C, H  |
| 33  | (EtO <sub>2</sub> C) <sub>2</sub> CH-                                    | -(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> Et | 170-174 (0.15)       | L           | 70          | IV                            | C <sub>18</sub> H <sub>20</sub> O <sub>6</sub> | C, H  |
| 34  | (EtO <sub>2</sub> C) <sub>2</sub> CMe                                    | -(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> Et | 150-154 (0.2)        | M           | 70          | IV                            | C <sub>19</sub> H <sub>20</sub> O <sub>6</sub> | C, H  |
| 35  | HO <sub>2</sub> C(CH <sub>2</sub> ) <sub>2</sub> -                       | -CH(Me)CO <sub>2</sub> Et                           | 175-177 (0.25)       | N           | 45          | IV                            | C <sub>13</sub> H <sub>16</sub> O <sub>4</sub> | OEt   |

<sup>a</sup> The compounds (14, 15, 24, and 39) of this table were tested on the carrageenan edema test but were inactive. <sup>b</sup> I, recrystallization from 50% aqueous EtOH; II, precipitated with acid, filtered, and washed with 50% EtOH; III, recrystallization from light petroleum (bp 60-80 °C); IV, distillation. <sup>c</sup> Reference 8 gives mp 164-165 °C.

Table III. Indan Series (Including Some Intermediates of Indan Structure)

| no. | R <sup>1</sup> | R <sup>2</sup>                       | R <sup>3</sup>                                    | R <sup>4</sup>                       | mp or bp<br>(mm), °C | meth-<br>od | yield,<br>% | purifn<br>proced <sup>a</sup> | formula   | anal.    | antiinflam<br>act. vs.   |  |
|-----|----------------|--------------------------------------|---|--------------------------------------|----------------------|-------------|-------------|-------------------------------|---|----------|--------------------------|--|
|     |                |                                      |   |                                      |                      |             |             |                               |   |          | dose,<br>mg/kg<br>po × 2 | ca. LD <sub>50</sub><br>in mice,<br>mg/kg po |
| 16  | O              | H <sub>2</sub>                       | H <sub>2</sub>                                    | H                                    | 151                  | H           | 56          | I                             | C <sub>17</sub> H <sub>14</sub> O <sub>3</sub>                        | C, H     | 100                      | 1600   |
| 17  | O              | H <sub>2</sub>                       | H <sub>2</sub>                                    | 6-CH <sub>2</sub> CO <sub>2</sub> H  | 133-135              | H           | 80          | II                            | C <sub>11</sub> H <sub>10</sub> O <sub>3</sub>                        | C, H     | 100                      | 1600   |
| 18  | O              | PhCH                                 | H <sub>2</sub>                                    | 6-CH <sub>2</sub> CO <sub>2</sub> H  | 202-204              | J           | 60          | III                           | C <sub>18</sub> H <sub>14</sub> O <sub>3</sub>                        | C, H     | 100                      | 1600   |
| 19  | O              | 4-ClC <sub>6</sub> H <sub>4</sub> CH | H <sub>2</sub>                                    | 6-CH <sub>2</sub> CO <sub>2</sub> H  | 264-266              | J           | 49          | IV                            | C <sub>18</sub> H <sub>13</sub> ClO <sub>3</sub>                      | C, H, Cl | 100                      | 1600   |
| 22  | O              | H <sub>2</sub>                       | H, Me   | 6-Ph                                 | 140-142 (0.2)        | H           | 71          | V                             | C <sub>16</sub> H <sub>14</sub> O                                     | C, H     | 100                      | 1600   |
| 23  | H <sub>2</sub> | H <sub>2</sub>                       | H, Me   | 6-Ph                                 | 43-45                | R           | 34          | VI                            | C <sub>16</sub> H <sub>16</sub>                                       | C, H     | 100                      | 1600   |
| 25  | O              | H <sub>2</sub>                       | H, Me   | 5-Ph                                 | 74-75.5              | T           | 4           | V, VII                        | C <sub>16</sub> H <sub>16</sub> O                                     | C, H     | NT <sup>j</sup>          | NT   |
| 30  | O              | H <sub>2</sub>                       | H, c-C <sub>6</sub> H <sub>11</sub>               | 6-CH <sub>2</sub> CO <sub>2</sub> H  | 153-155              | H           | 32          | VIII                          | C <sub>17</sub> H <sub>20</sub> O <sub>3</sub>                        | C, H     | 100                      | 1200   |
| 31  | H <sub>2</sub> | H <sub>2</sub>                       | H <sub>2</sub> , c-C <sub>6</sub> H <sub>11</sub> | 6-CH <sub>2</sub> CO <sub>2</sub> Na | 160                  | W           | 100         | IX                            | C <sub>17</sub> H <sub>21</sub> O <sub>2</sub> Na·1.7H <sub>2</sub> O | C, H     | 100                      | 1200   |
| 36  | O              | H <sub>2</sub>                       | H <sub>2</sub>                                    | 6-CH(Me)CO <sub>2</sub> Et           | 137-144 (0.2)        | H           | 46          | V                             | C <sub>14</sub> H <sub>16</sub> O <sub>3</sub>                        | C, H     | NT                       | NT   |
| 37  | O              | H <sub>2</sub>                       | H <sub>2</sub>                                    | 6-CH(Me)CO <sub>2</sub> H            | 109                  | P           | 42          | III                           | C <sub>12</sub> H <sub>12</sub> O <sub>3</sub>                        | C, H     | NT                       | NT   |
| 38  | O              | 4-ClC <sub>6</sub> H <sub>4</sub> CH | H <sub>2</sub>                                    | 6-CH(Me)CO <sub>2</sub> H            | 206-208              | J           | 38          | IV                            | C <sub>19</sub> H <sub>15</sub> ClO <sub>3</sub>                      | C, H, Cl | NT <sup>m</sup>          | NT   |

<sup>a</sup> I, trituration with Et<sub>2</sub>O; II, recrystallization from C<sub>6</sub>H<sub>6</sub>; III, recrystallization from 50% aqueous EtOH; IV, recrystallization from 96% EtOH; V, distillation; VI, preparative gas chromatography (D. N. B. Mallen and D. J. Osborne); VII, recrystallization from light petroleum (bp 60-80 °C); VIII, trituration with Me<sub>2</sub>CO-light petroleum (bp 40-60 °C) (1:3); IX, evaporation of an aqueous EtOH solution. <sup>b</sup> An asterisk indicates that the result is significant on Student's *t* test at *p* < 0.01. <sup>c</sup> Control compound hydrocortisone gave 52% reduction of edema at 2 × 50 mg/kg po (*p* < 0.001). <sup>d</sup> Phenylbutazone control: 40% reduction at 2 × 50 mg/kg po (*p* < 0.02). <sup>e</sup> Phenylbutazone control: 43% reduction at 2 × 50 mg/kg po (*p* < 0.05). <sup>f</sup> Phenylbutazone control: 65% reduction at 2 × 50 mg/kg (*p* < 0.01). <sup>g</sup> Phenylbutazone control: 51% reduction at 2 × 50 mg/kg (*p* < 0.001). <sup>h</sup> Phenylbutazone control: 53% reduction at 2 × 50 mg/kg (*p* < 0.01). <sup>i</sup> In the rat adjuvant arthritis test, compound 16 showed 52% reduction in swelling of the noninjected foot at 16 × 100 mg/kg and control compound phenylbutazone, 42% reduction at 16 × 100 mg/kg; compound 18 showed 25% reduction at 16 × 100 mg/kg and control compound indomethacin 57% reduction at 16 × 1 mg/kg; compound 19 showed 43% reduction at 16 × 100 mg/kg; control compound phenylbutazone, 42% reduction at 16 × 33 mg/kg; compound 38 showed 53% reduction at 16 × 100 mg/kg and control compound indomethacin, as before; compound 23 showed 32% reduction at 16 × 50 mg/kg.



evaporated, and the residue was distilled to give the esters 2: yield 83.6 g; bp 145–155 °C (0.1 mm). Similarly prepared were the esters 10, R = H [yield 65%; bp 255–265 °C (0.15 mm)] and R = Me [yield 73%; bp 180–190 °C (0.15 mm)], both with the ketone 9 as starting material.

**Method B (i).** The mixture of esters 2 was hydrogenated over 10% Pd/C (0.6 g) to give ethyl 3-phenylindan-1-acetate (84.3 g; 3). Similarly, from the ester 26 was prepared the ester 27: bp 100–102 °C (0.12 mm);  $n_D^{25}$  1.5042; NMR  $\delta$  1.02 (3 H), 0.6–2.0 (12 H), 2.5–3.0 (2 H), 3.9 (2 H), 7.15 (5 H).

**Method B (ii).** Ester 3 was hydrolyzed under standard alkaline conditions to give the acetic acid 4 (see Table I). Similarly prepared were the acids 12, R = H and Me, from the corresponding esters 11.

**Methods C and D. 3-(3-Phenyl-1-indan)propionic Acid (8).** The ester 3 (84.3 g, 0.3 mol) in THF (300 mL) was added dropwise with stirring to LiAlH<sub>4</sub> (10 g) in THF (200 mL) under N<sub>2</sub>, and the mixture was stirred at 80 °C overnight. Processing by standard conditions yielded the alcohol 5 as an oil: yield 47.3 g; IR 3100–3600 cm<sup>-1</sup> (OH). This alcohol was also obtained by reduction of the ester in THF using LiBH<sub>4</sub>. The alcohol 5 (43.15 g, 0.18 mol) was refluxed overnight with 48% HBr (280 mL), cooled, and extracted with ether, which with standard processing gave the bromo compound 6 (50.8 g) as an oil. The bromo compound 6 (41.8 g, 0.14 mol) in Me<sub>2</sub>CO (160 mL) was added to a solution of NaCN (7 g, 0.143 mol) in H<sub>2</sub>O (40 mL), and the solution was stirred and refluxed for 64 h. The solution was evaporated to dryness and the product extracted with a mixture of AcOEt and H<sub>2</sub>O. After drying (Na<sub>2</sub>SO<sub>4</sub>), filtration and evaporation of the mixture, the nitrile 7 (26.8 g) was obtained as a solid: IR 2250 cm<sup>-1</sup> (CN). The nitrile 7 (24.3 g, 0.1 mol) in hot EtOCH<sub>2</sub>CH<sub>2</sub>OH (100 mL) was treated with NaOH (24.3 g, 0.6 mol) in H<sub>2</sub>O (40 mL), and the solution was refluxed for 6 h. It was poured into concentrated HCl (50 mL) in H<sub>2</sub>O (250 mL) and extracted with Et<sub>2</sub>O, and the Et<sub>2</sub>O was extracted with 2 N NaOH. Acidification gave the acid 8, purified as in Table I: NMR (CCl<sub>4</sub>)  $\delta$  1.5–3.3 (7 H, CH<sub>2</sub>), 4.12 (1 H, CH), 6.8–7.3 (9 H, Ar), 11.92 (1 H, exchangeable).

**Method E. 1-Phenyl-2a,3,4,5-tetrahydro-5-acenaphthenone (9).** The acid 8 (32 g, 0.12 mol) was dried by refluxing in C<sub>6</sub>H<sub>6</sub> (200 mL) with removal of azeotroped H<sub>2</sub>O. The solution was added to a stirred suspension of PCl<sub>5</sub> (29 g, 0.14 mol) in C<sub>6</sub>H<sub>6</sub> (50 mL) and stirred for 1.5 h. The solution was added to a cooled stirred suspension of AlCl<sub>3</sub> (29 g) in C<sub>6</sub>H<sub>6</sub> and stirred at room temperature for 3 h. The mixture was poured into ice and HCl and extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O was washed (NaHCO<sub>3</sub> solution), dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated to give the ketone 9 [yield 25.7 g; mp 99 °C] from MeOH. Anal. (C<sub>18</sub>H<sub>16</sub>O) C, H.

**Method F. Ethyl 1-Phenyl-5-acenaphthenylacetate (11, R = H).** The ester 10, R = H (18.3 g, 0.058 mol), was stirred with 10% Pd/C (1.8 g) under N<sub>2</sub> at 200–210 °C for 2 h. The cooled product dissolved in CHCl<sub>3</sub> was filtered and evaporated to give the ester as an oil (17.9 g). Similarly prepared was the ester 11, R = Me, from the ester 10, R = Me.

**Method G. 4-(2-Carboxyethyl)phenylacetic Acid (14) and 4-(1-Cyclohexyl-2-carboxyethyl)phenylacetic Acid (29).** The procedure of Schwenk and Papa<sup>13</sup> [for 4-(carboxymethyl)phenylacetic acid] was followed exactly to obtain compound 14 from 13.<sup>14</sup> Similarly, compound 29 was obtained from 28 as a brown oil: IR (film) 1708 cm<sup>-1</sup>.

**Method H. 1-indanone-6-acetic Acid (17).** Polyphosphoric acid (1 kg) was stirred and heated to 95–100 °C, and the acid (14, 100 g, 0.48 mol) was added over 10 min. The mixture was stirred for 0.5 h and poured into ice and H<sub>2</sub>O; the product was continuously extracted with CHCl<sub>3</sub> and purified as indicated in Table III. This method was used to cyclize the acid 20a<sup>15</sup> to the indanone 22, the acid ester 35 to the indanone ester 36 (for the latter a temperature of 70–75 °C was used for the reaction), and the diacid 15 to the acid 16.

**Method J. 2-Benzylidene-3-oxo-5-indanacetic Acid (18).** The acid 17 (4.94 g, 0.026 mol) was added to a stirred solution of 85% KOH (3.43 g, 0.052 mol) in EtOH (73 mL) containing PhCHO (2.76 g, 0.026 mol) at 10 °C and stirred 40 min. The K salt of the precipitated product was filtered off, dissolved in H<sub>2</sub>O (100 mL), and acidified with concentrated HCl to give the acid 18, which was purified as in Table III. This method was

used for the acids 19 and 38, but, instead of isolating the K salts, the products were isolated by diluting the reaction solutions with 20 times their volumes of water before acidification.

**Method K. Ethyl 4-(2-Carbethoxyethyl)phenylacetate (32).** 4-(2-Carboxyethyl)phenylacetic acid (14; 20.82 g, 0.1 mol) was refluxed overnight in EtOH (416 mL) containing concentrated HCl (10.8 mL). The solvent was evaporated and the ester distilled.

**Method L.<sup>16</sup> Diethyl 4-(2-Carbethoxyethyl)phenylmalonate (33).** The diester 32 (340 g, 1.29 mol) was stirred in diethyl carbonate (1975.4 g, 16.7 mol) at 80–100 °C and treated with a solution of sodium (29.58 g, 1.29 mol) in EtOH (687 mL), and the mixture was stirred and distilled until the distillate temperature reached 123 °C. After storage in a refrigerator overnight, the solution was treated with AcOH (142 mL) in H<sub>2</sub>O (567 mL) and extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O was washed with saturated NaHCO<sub>3</sub> and saturated NaCl solutions, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated, and the residue was distilled to give 33. NMR showed that the product contained ca. 22% of 32.

**Method M. Diethyl Methyl[4-(2-carboxyethyl)phenyl]malonate (34).** The tricarboxylic ester (33; 300 g, 0.89 mol) in EtOH (200 mL) was added to a warm solution of sodium (20.7 g, 0.9 mol) in EtOH (700 mL). Methyl iodide (322.5 g, 2.34 mol) was added, the solution was stirred and refluxed for 40 min, and further MeI (332.5 g) was added and then added again (196.1 g, 1.4 mol) after 2 h. After a total reflux for 3 h, the solution was evaporated, H<sub>2</sub>O was added, and the mixture was extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O solution was processed as in method L to give 34:  $n_D^{21}$  1.4920; NMR showed that it contained 75–77% of the required material.

**Method N. Ethyl Methyl[4-(2-carboxyethyl)phenyl]acetate (35).** The tricarboxylic ester 34 (35 g, 0.1 mol) in EtOH (400 mL) was stirred at room temperature with a solution of KOH (13.2 g of 85%, 0.2 mol) in EtOH (100 mL) for 96 h. The mixture was evaporated to dryness. The solid foam was broken up, treated with Et<sub>2</sub>O (200 mL), and filtered. The residue was dissolved in H<sub>2</sub>O (100 mL) and acidified with 5 N HCl to give an oil which was extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to give an oily solid. The solid was shaken with a mixture of CHCl<sub>3</sub>–light petroleum (bp 40–60 °C) (100 mL of 50:50) and filtered, the residue was washed with the same solvent mixture (100 mL), and the filtrate was evaporated to leave an oil, which was distilled to give 35.

**Method P. Methyl(3-oxo-5-indan)acetic Acid (37).** The ester 37 (9 g, 0.038 mol) in AcOH (90 mL) was added to concentrated HCl (90 mL) and kept at room temperature for 5 days. The solution was poured into H<sub>2</sub>O (1 L) and extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O was washed with saturated NaCl solution, dried (MgSO<sub>4</sub>), filtered, and evaporated. The product was further purified by dissolving in saturated NaHCO<sub>3</sub> solution (100 mL), extracting with Et<sub>2</sub>O and acidifying the aqueous phase to give 37. A sample was recrystallized for analysis.

**Method R. 1-Methyl-5-phenylindan (23).** This method was the same as for method B, except that concentrated HCl (1.58 mL for 1.05 g, 10% Pd/C) was added to the hydrogenation mixture. The method was also used for preparation of the acid of the salt 31 from the keto acid 30.

**Method S. 4-Biphenyl Propenyl Ketone (24).** This method followed that given by Fieser and Herschberg for 3-crotonylacenaphthene.<sup>17</sup>

**Method T.<sup>18</sup> 3-Methyl-5-phenylindanone (25).** The above unsaturated ketone 24 (10 g, 0.045 mol) was added to a finely powdered mixture of AlCl<sub>3</sub> (50 g, 0.37 mol) and NaCl (10 g) which had been stirred and heated to 140 °C. The mixture was kept at 140–180 °C for 2 min with stirring, poured into ice, and treated with concentrated HCl (15 mL). The product was extracted with CHCl<sub>3</sub>, which was washed with saturated NaHCO<sub>3</sub> and saturated NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, evaporated, and further purified as indicated in Table III, bp 131–134 °C (0.1 mm). Distillation gave a mixture of liquid and solid. The latter was separated and recrystallized.

**Method U. Ethyl 3-Cyclohexyl-3-phenylacrylate (26).** Ethyl bromoacetate (82.55 g, 0.49 mol) and cyclohexyl phenyl ketone (91.6 g, 0.49 mol) were reacted according to method A, and the resulting  $\beta$ -hydroxy ester [yield 134.58 g; bp 103–109 °C (0.06 mm)] was refluxed in benzene (350 mL) for 3.5 h. Phosphorus pentoxide (50 g) was added before reflux began, and it

was again (50 and 33 g) added 1.5 and 2 h after reflux began. The cooled solution was filtered and dried ( $K_2CO_3$ ), and the product was distilled: bp 105–109 °C (0.06 mm);  $n_D^{20}$  1.5196 (not analytically pure). NMR showed that it contained 67% of the isomer designated as 26, and the remainder was mainly the  $\beta,\gamma$ -doubly bonded ester.

**Method V. Ethyl 3-Cyclohexyl-3-(4-acetylphenyl)-propionate (28).** The ester 27 (56 g, 0.215 mol) was acetylated using the method which Baddeley employed for the preparation of methyl 3-(4-acetylphenyl)propionate.<sup>14</sup>

**Method W. 1-Cyclohexyl-5-indanacetic Acid, Sodium Salt (31).** The acid 30 (24.6 g, 0.09 mol) was reduced using the method [employed to prepare  $\beta$ -(*p*-phenoxybenzoyl)propionic acid] of ref 19 to give 1-cyclohexylindan-5-acetic acid: bp 158–162 °C (0.06 mm);  $n_D^{20}$  1.5452. Anal. ( $C_{17}H_{22}O_2$ ) C, H. The acid was converted to its sodium salt by adding aqueous  $NaHCO_3$  to an EtOH solution of the acid, followed by evaporation.

**Acknowledgment.** We thank Dr. D. M. Rackham and Mr. R. C. Harden for the determination and interpretation of spectral results and Dr. D. N. B. Mallen and Mr. D. J. Osborne for the purification of compound 23.

## References and Notes

- (1) For Part 2, see: J. C. Saunders and W. R. N. Williamson, *J. Med. Chem.*, **22**, see Notes section in this issue (1979).
- (2) Cf. T. Y. Shen, *Angew. Chem., Int. Ed. Engl.*, **11**, 460 (1972).
- (3) Unpublished work.
- (4) Mizushima test; for references, see p. 78 of "Antiinflammatory Agents", Vol. II (Vol. 13 of "Medicinal Chemistry"), Academic Press, New York, 1974, p 78.
- (5) Cf. "Detoxication Mechanisms", R. T. Williams, Chapman and Hall, London, 1959, p 201.
- (6) A. W. Pircio, M. E. Bierwagen, W. E. Strife, and W. D. Nicolasi, *Arch. Int. Pharmacodyn.*, **199**, 151–163 (1972).
- (7) A. G. Anderson, Jr., and R. H. Wade, *J. Am. Chem. Soc.*, **74**, 2274 (1952).
- (8) T. C. Bruice and W. C. Bradbury, *J. Org. Chem.*, **28**, 3403 (1963).
- (9) W. Baker, J. F. W. McOmie, S. D. Parfitt, and D. A. M. Watkins, *J. Chem. Soc.*, 4026 (1957).
- (10) C. A. Winter, E. A. Risley, and G. W. Nuss, *Proc. Soc. Exp. Biol. Med.*, **111**, 544 (1962).
- (11) D. W. Dunwell, D. Evans, T. A. Hicks, C. H. Cashin, and E. A. Kitchen, *J. Med. Chem.*, **18**, 53 (1975).
- (12) B. B. Newbould, *Br. J. Pharmacol.*, **21**, 127 (1963).
- (13) E. Schwenk and D. Papa, *J. Org. Chem.*, **11**, 798 (1946).
- (14) G. Baddeley and R. Williamson, *J. Chem. Soc.*, 4647 (1956).
- (15) C. H. Eades, Jr., C. M. Weiss, V. B. Solberg, and G. E. Phillips, *Med. Pharmacol. Exp.*, **14**, 225 (1966).
- (16) Cf. Irish Patent 56/65 (Boots & Co.).
- (17) L. F. Fieser and E. B. Hershberg, *J. Am. Chem. Soc.*, **61**, 1272 (1939).
- (18) D. B. Bruice, A. J. S. Sorrie, and R. H. Thomson, *J. Chem. Soc.*, 2403 (1953).
- (19) D. Todd in "Organic Reactions", Vol. IV, R. Adams, Ed., Wiley, New York, 1948, p 391.

## N-Alkylated 2-Aminotetralins: Central Dopamine-Receptor Stimulating Activity

Uli Hacksell,\* Uno Svensson, J. Lars G. Nilsson,

Department of Organic Pharmaceutical Chemistry, Biomedical Center, University of Uppsala, S-751 23 Uppsala, Sweden

Stephan Hjorth, Arvid Carlsson,

Department of Pharmacology, University of Gothenburg, Fack, S-400 33 Göteborg, Sweden

Håkan Wikström, Per Lindberg, and Domingo Sanchez

Organic Chemistry Unit, Department of Pharmacology, University of Gothenburg, S-400 33 Göteborg, Sweden.

Received May 15, 1979

In order to define the structural requirements of N-substituents of 2-aminotetralins as central dopamine receptor agonists, a series of N-alkyl- and N,N-dialkyl-substituted 2-amino-5-hydroxy- and 2-amino-5-methoxytetralins have been synthesized and evaluated. The compounds were tested biochemically and behaviorally for dopaminergic activity. From the biochemical data it is concluded that an *n*-propyl group on the nitrogen is optimal for activity. The corresponding N-ethyl-substituted compounds are slightly less active, while the absence of N-ethyl or N-propyl groups give almost inactive compounds. It could be demonstrated that this is due to steric and not to lipophilic factors. It is suggested that a possible requirement for a potent agonist is that one of its N substituents must fit into a receptor cavity which, because of its size, can maximally accommodate an *n*-propyl but also smaller groups like ethyl or methyl. The active compounds appeared to give a similar relative pre- and postsynaptic stimulation and had also similar activities for the limbic system and for striatum. None of the compounds listed seemed to have central noradrenaline- or serotonin-receptor stimulating activity.

The high dopamine-receptor stimulating activity of apomorphine has been the basis of many structure-activity relationship studies. These include apomorphine derivatives<sup>1,2</sup> as well as various simplified structural analogues.<sup>3–6</sup> The bicyclic analogues 2-amino-5,6- and 2-amino-6,7-dihydroxytetralin and several of their N-alkylated derivatives have been shown to possess central dopamine-receptor stimulating activity.<sup>5–12</sup> Some of these compounds are even more potent than apomorphine.

The N-butyl or N,N-dibutyl derivatives of 2-amino-5,6-dihydroxytetralin, dopamine, or norapomorphine have very little or no dopaminergic activity, while the analogues carrying at least one N-ethyl or one N-*n*-propyl group possess high activity.<sup>1,6,7,10–15</sup> The results thus obtained

in different investigations show that the structure of the N-alkylamino moiety of dopamine-related compounds is important for the dopamine-receptor stimulating activity. We have now investigated an extensive series of N-alkylated 2-aminotetralins in order to establish the influence of the N substituents upon the dopaminergic activity.

The monohydroxy derivative 5-hydroxy-2-(dipropylamino)tetralin has been reported to be almost equipotent to its 5,6-catechol analogue in producing stereotypy in rats and emesis in dogs.<sup>16</sup> This high potency of the 5-hydroxy derivative, together with the fact that monophenolic compounds are chemically more stable than catechols, induced us to choose the 2-amino-5-hydroxytetralin unit as the basic structure in our investigation. One could also expect